Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $80.00

Xenon Pharmaceuticals (NASDAQ:XENE) had its target price raised by Needham & Company LLC from $58.00 to $80.00 in a research note issued to investors on Monday,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on XENE. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Jefferies Financial Group reissued a “buy” rating and issued a $65.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday. Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th. JPMorgan Chase & Co. lifted their target price on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Finally, Wolfe Research began coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $71.94.

Xenon Pharmaceuticals Trading Down 2.6%

XENE stock opened at $59.04 on Monday. The company has a market cap of $4.91 billion, a PE ratio of -13.54 and a beta of 0.91. The stock has a 50-day moving average price of $43.23 and a two-hundred day moving average price of $41.69. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the prior year, the firm posted ($0.84) earnings per share. Equities analysts forecast that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.

Insider Activity

In related news, insider Andrea Difabio sold 2,607 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $156,706.77. Following the completion of the sale, the insider directly owned 4,893 shares of the company’s stock, valued at approximately $294,118.23. This trade represents a 34.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ian Mortimer sold 11,269 shares of Xenon Pharmaceuticals stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $677,379.59. Following the sale, the chief executive officer directly owned 14,731 shares in the company, valued at $885,480.41. This trade represents a 43.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 326,647 shares of company stock worth $19,066,951 over the last 90 days. Company insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

Large investors have recently modified their holdings of the business. Cinctive Capital Management LP increased its position in shares of Xenon Pharmaceuticals by 1.1% during the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after acquiring an additional 263 shares during the last quarter. Arizona State Retirement System boosted its holdings in Xenon Pharmaceuticals by 1.8% in the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock valued at $774,000 after purchasing an additional 334 shares during the last quarter. State of Wyoming boosted its holdings in Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 350 shares during the last quarter. Quarry LP grew its stake in Xenon Pharmaceuticals by 25.0% during the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 500 shares in the last quarter. Finally, Altfest L J & Co. Inc. grew its stake in Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 501 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals News Summary

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 trial: azetukalner met its goal in focal‑onset seizures and Xenon said it plans an NDA filing in 3Q‑2026 — a clear clinical milestone that supports future revenue potential. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets (Wells Fargo, Wedbush, HC Wainwright, Deutsche Bank and others) increased street conviction and pushed consensus targets materially above prior levels. That analyst momentum typically supports share appreciation. Deutsche Bank Raises XENE Price Target
• Positive Sentiment: Independent analyst commentary (Needham) expects further upside, reinforcing the buy‑side narrative around azetukalner’s market opportunity. Xenon Pharmaceuticals Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Earlier reports noted a proposed $500M offering; that story evolved as management and bankers adjusted size and pricing in response to demand and market conditions. The initial notice itself was informational. Xenon Pharmaceuticals announces proposed $500M public share offering
• Negative Sentiment: Upsized public offering priced at $57.00 per share to raise ~ $650M (with a 30‑day option for additional shares). While the cash strengthens the balance sheet and funds registrational/launch activities, the scale of the sale increases near‑term dilution and likely pressured the stock despite positive trial and analyst news. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.